Table 1.
Baseline socio-demographic and clinical characteristics of active ankylosing spondylitis patients treated with adalimumab (n = 91).
| Characteristics | Mean (SD) |
|---|---|
| Age (year) | 30.58 (7.76) |
| Sex (male), n (%) | 79 (87.78%) |
| Marital status, n (%) | |
| Single | 44 (48.35%) |
| Married | 46 (50.55%) |
| Divorced | 1 (1.1%) |
| Education, n (%) | |
| Middle school or less | 25 (27.47%) |
| High school | 36 (39.56%) |
| College or more | 30 (32.97%) |
| Employment, n (%) | 71 (78.02%) |
| Work productivity loss (0–1) | 0.28 (0.28) |
| WAPI:SpA | |
| Absenteeism | 10.22% (19.44%) |
| Presenteeism | 43.86% (22.48%) |
| Work productivity loss | 47.92% (25.81%) |
| Activity impairment | 48.57% (22.02%) |
| Disease duration (year) | 9.99 (6.93) |
| Delayed diagnosis time (year) | 3.62 (4.69) |
| HLA-B27 positive, n (%) | 78 (85.71%) |
| Positive family history, n (%) | 33 (36.26%) |
| BASDAI (0–10) | 5.31 (1.02) |
| BASFI (0–10) | 4.23 (1.92) |
| BASMI (0–10) | 2.98 (2.47) |
| ASDAS-CRP | 3.54 (0.80) |
| ASQoL | 9.1 (3.81) |
| EQ-5D | 0.58 (0.22) |
| CRP | 23.89 (19.82) |
| ESR | 29.08 (21.90) |
| Biologic agents used before, n (%) | 56 (61.54%) |
SD, Standard Deviation; WPAI:SpA, Work productivity and activity impairment questionnaire in AS; HLA-B27, Human leukocyte antigen-B27; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; EQ-5D, EuroQol-5 Dimensions; CRP, C-Reactive Protein; ESR, Erythrocyte Sedimentation Rate.